Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study

Breast Cancer Clinical Trial

— ATD  

Official title:

Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study. ATD-Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06272799
• Other study ID #: RS1480/21
• Status: Recruiting
• Start date: September 20, 2022
• Est. completion date: September 20, 2024

Study information

• Verified date: February 2024
• Source: Regina Elena Cancer Institute
• Contact: Patrizia Vici, Doctor
• Phone: 06-5266.5698
• Email: patrizia.vici[@]ifo.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

Description:

Patients affected by will be included in the study and analyzed HER2 positive breast cancer with residual invasive disease after neoadjuvant chemotherapy, treated consecutively with adjuvant T-DM1 at the various Italian oncology centers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: September 20, 2024
• Est. primary completion date: September 20, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histological diagnosis of HER2 positive breast cancer;

• Presence of invasive residual disease on T or N after neoadjuvant chemotherapy including anti-HER2 agents

• Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide;

• Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study;

• Written informed consent for the prospective part and, if possible, for the recruited patients retrospectively

Exclusion Criteria:

• Concomitant treatments with other biological agents;

• Absence of clinical data that allow the correct analysis of the primary and secondary objectives;

• Patients with a history of other malignant neoplasms;

• Contraindications to the use of T-DM

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• T-DM1 adjuvant
Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events

Locations

Country	Name	City	State
Italy	"Regina Elena" National Cancer Institute	Rome

Sponsors (1)

Lead Sponsor	Collaborator
Regina Elena Cancer Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the tolerability.	Evaluate the tolerability of the treatment in terms of adverse events, defined according to Common Terminology Criteria for Adverse Events (CTCAE, version 4), in a population of patients treated with adjuvant T-DM1 in "real life"	24 months
Secondary	Evaluate the effectiveness of treatment.	Evaluate in the "real life setting" the effectiveness of adjuvant treatment in terms of survival free from disease (Disease Free Survival, DFS) in patients with HER2 positive breast cancer and residual invasive disease (on T and/or on N) after neoadjuvant chemotherapy.	24 months